Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening.

Abstract Endometrial disorders represent a major gynaecological burden. Current research models fail to recapitulate the nature and heterogeneity of these diseases, thereby hampering scientific and clinical progress. Here we developed long-term expandable organoids from a broad spectrum of endometrial pathologies. Organoids from endometriosis show disease-associated traits and cancer-linked mutations. […]

Click here to view original web page at Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening.